Skip to Content


Active Substance: lutetium (177 Lu) chloride
Common Name: lutetium (177 Lu) chloride
ATC Code: V10X
Marketing Authorisation Holder: ITG Isotope Technologies Garching GmbH
Active Substance: lutetium (177 Lu) chloride
Status: Authorised
Authorisation Date: 2016-07-06
Therapeutic Area: Radionuclide Imaging
Pharmacotherapeutic Group: Therapeutic radiopharmaceuticals

Therapeutic Indication

EndolucinBeta is a radiopharmaceutical precursor, and it is not intended for direct use in patients. It is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with Lutetium (177Lu) chloride.

What is EndolucinBeta and what is it used for?

EndolucinBeta contains the radioactive compound lutetium (177Lu) chloride and is used for radiolabelling other medicines. Radiolabelling is a technique for tagging (or labelling) medicines with radioactive compounds so they can carry radioactivity to where it is needed in the body, for example the site of a tumour.

EndolucinBeta is only to be used to radiolabel medicines that have been specifically developed for use with lutetium (177Lu) chloride.

How is EndolucinBeta used?

EndolucinBeta is only used by specialists who have experience in radiolabelling.

EndolucinBeta is never given to a patient on its own. Radiolabelling with EndolucinBeta takes place in a laboratory. The radiolabelled medicine is then given to the patient according to the instructions in that medicine’s product information.

How does EndolucinBeta work?

The active substance in EndolucinBeta, lutetium (177Lu) chloride, is a radioactive compound that mainly emits a type of radiation known as beta radiation, with small amounts of gamma radiation. When a medicine radiolabelled with EndolucinBeta is given, it carries the radiation to where it is needed in the body, either to kill cancer cells (when used for treatment) or to obtain images on a screen (when used in diagnosis).

What benefits of EndolucinBeta have been shown in studies?

Several published studies have established the usefulness of lutetium (177Lu) in radiolabelling medicines for diagnosing and treating neuroendocrine tumours. This is a group of tumours that affect hormone-secreting cells in many parts of the body, including the pancreas, intestine, stomach and lungs. The benefits of EndolucinBeta will largely depend on the medicine that it is used to radiolabel.

What are the risks associated with EndolucinBeta?

The side effects with EndolucinBeta depend largely on the medicine it is used with and will be described in that medicine’s package leaflet. EndolucinBeta itself is radioactive, and as with any other radioactive product, its use may carry a risk of developing cancer and defects that are passed on to children. However, the quantity of EndolucinBeta to be used is very small and therefore these risks are considered low. The doctor will ensure that the expected benefit to the patients of using EndolucinBeta outweigh the risks linked to the radioactivity.

The most common side effects with EndolucinBeta (which may affect more than 1 in 10 people) are anaemia (low red blood cell counts), thrombocytopenia (low blood platelet counts), leucopenia (low white blood cell counts), and lymphopenia (low levels of lymphocytes, a particular type of white blood cell).

Medicines radiolabelled with EndolucinBeta must not be used in pregnant women or women who may be pregnant. For the full list of all side effects and restrictions with EndolucinBeta, see the package leaflet. Information on restrictions that apply specifically to medicines radiolabelled with EndolucinBeta can be found in the package leaflets of those medicines.

Why is EndolucinBeta approved?

The European Medicines Agency considered that the use of lutetium (177Lu) for radiolabelling medicines was well documented in the scientific literature. As with all radiolabelling materials for medicines, there are risks linked to radiation exposure from EndolucinBeta. Information on how to minimise the risks is included in the product information for EndolucinBeta.

The Agency concluded that the benefits of EndolucinBeta outweigh the risks and recommended that it be given marketing authorisation.

What measures are being taken to ensure the safe and effective use of EndolucinBeta?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of EndolucinBeta have been included in the summary of product characteristics and the package leaflet.

Other information about EndolucinBeta

The European Commission granted a marketing authorisation valid throughout the European Union for EndolucinBeta on 06 July 2016.

For more information about treatment with EndolucinBeta, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.